Versant Venture Management, LLC - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 12, 2026, for the 2025 Q4 period, Versant Venture Management, LLC held in its portfolio 7 assets valued at $151,060,501 (i.e. $151.06M).

The most valuable assets in the portfolio included: Monte Rosa Therapeutics, Inc. ($68.72M), Lenz Therapeutics, Inc. ($42.51M), and Jade Biosciences, Inc. ($23.54M).

The chart below shows the top 7 valuable assets, and the table below shows the top 7 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in Versant Venture Management, LLC Portfolio

Monte Rosa Therapeutics, Inc.

Lenz Therapeutics, Inc.

Jade Biosciences, Inc.

CRISPR Therapeutics AG

Contineum Therapeutics, Inc.

Skye Bioscience, Inc.

Tempest Therapeutics, Inc.

Versant Venture Management, LLC - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
Monte Rosa Therapeutics, Inc.	4382687	68720532	Common Stock
Lenz Therapeutics, Inc.	2656888	42510208	Common Stock
Jade Biosciences, Inc.	1525820	23543403	Common Stock
CRISPR Therapeutics AG	148831	7804698	Common Shares
Contineum Therapeutics, Inc.	542628	6202238	Common Stock
Skye Bioscience, Inc.	2007704	1505176	Common Stock
Tempest Therapeutics, Inc.	269772	774246	Common Stock